Literature DB >> 2935830

[Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up].

L Guillevin, L Euller-Ziegler, B Chouvet, A De Gery, G Chassoux, P Lafay, G Ziegler, P Godeau, B Amor, J Thivolet.   

Abstract

Eighty-six patients with progressive systemic sclerosis were given coagulation factor XIII intravenously in different dosage regimens. The mean duration of treatment was 19 +/- 18 months and patients were followed up for 22.9 +/- 18.8 months. Improvement or stabilization of the lesions was obtained in 44/86 patients and exclusively concerned skin lesions; there was no improvement in visceral lesions. The drug was well tolerated in short-and long-term treatment. It is concluded that factor XIII demonstrated lasting effectiveness in one-half of the patients treated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935830

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

Review 1.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

2.  An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Authors:  Magalys Vitiello; Adriana Abuchar; Néstor Santana; Luis Dehesa; Francisco A Kerdel
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

Review 3.  Current therapy of systemic sclerosis (scleroderma).

Authors:  U Müller-Ladner; K Benning; B Lang
Journal:  Clin Investig       Date:  1993-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.